Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens

Similar documents
Clinical Practice Guidelines June 2013

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013

Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation

EU guidelines for reporting gynaecological cytology

Making Sense of Cervical Cancer Screening

BC Cancer Cervix Screening 2015 Program Results. February 2018

Cervical Cancer : Pap smear

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Chapter 10: Pap Test Results

Cervical Precancer: Evaluation and Management

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two

Pap Reports. Of all women undergoing Papanicolaou (Pap) What Now? Women s Health. What has changed?

Comparative Study of Pap Smear Quality by using Ayre s Spatula versus Ayre s Spatula and Cytobrush Combination

PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals

Colposcopy. Attila L Major, MD, PhD

Cervical Dysplasia and HPV

Understanding Your Pap Test Results

Histopathology: Cervical HPV and neoplasia

Lessons From Cases of Screened Women Who Developed Cervical Carcinoma

Cervical Screening for Dysplasia and Cancer in Patients with HIV

!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series

An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia

GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital

The ABCs of TBS. A Novice's Guide to the Bethesda System

ANALYSES OF CERVICAL CANCER IN RAJKOT POPULATION

The society for lower genital tract disorders since 1964.

Can LBC Completely Replace Conventional Pap Smear in Developing Countries

Cytology Report Format

Int. J. Life. Sci. Scienti. Res., 2(3): (ISSN: ) Impact Factor 2.4 MAY Research Article (Open access)

Table of Contents. 1. Overview. 2. Interpretation Guide. 3. Staining Gallery Cases Negative for CINtec PLUS

Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.

Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH

HKCOG GUIDELINES NUMBER 3 (revised November 2002) published by The Hong Kong College of Obstetricians and Gynaecologists

Management Algorithms for Abnormal Cervical Cytology and Colposcopy

Cervical Cancer Screening Update. Melissa Hartman, DO Women s Health

Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary

Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing

Cytyc Corporation - Case Presentation Archive - July 2002

Cervical Cancer Screening. David Quinlan December 2013

January 15, 2009 (202) PROPOSALS TO IMPROVE CYTOLOGY PROFICIENCY TESTING REQUIRED BY THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988

Eradicating Mortality from Cervical Cancer

ACGME Competency / Milestone Assessment. The Pap Test. Ricardo R. Lastra, MD Zubair W. Baloch, MD, PhD

Manitoba Cervical Cancer Screening Program. Operations & Statistical Report and 2006

LGM International, Inc.

Objectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies

chapter 4. The effect of oncogenic HPV on transformation zone epithelium

GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

I have no financial interests to disclose.

Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.

National Cervical Screening Program MBS Item Descriptors

HPV Testing & Cervical Cancer Screening:

How invasive cervical cancer audit affects clinical practice

PAP smear. (Papanicolaou Test)

Pushing the Boundaries of the Lab Diagnosis in Asia

International Journal of Biological & Medical Research

Cervical Skills. Dr Margaret Laing Queen Elizabeth University Hospital

CINtec p16 INK4a Staining Atlas

PREVENTION OF CERVICAL CANCER

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

International Journal of Health Sciences and Research ISSN:

I have no financial interests in any product I will discuss today.

New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology

COMPARATIVE STUDY OF LIQUID BASED CYTOLOGY AND PAP SMEAR IN CANCER CERVIX SCREENING

CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN)

Course Title: Thin Prep PAP Smears. Number of Clock Hours: 3 Course Title #

Instructions For Use

Evaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions on Cervical Smear

Index. Cytoplasm, nonepithelial malignant tumor features 70

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells

Scottish Cervical Screening Programme. Colposcopy and Programme Management

A Study on Diagnostic Accuracy of Cervical Pap Smear by Correlating with Histopathology in a Tertiary Care Centre

Estimated New Cancers Cases 2003

Interpretation guide. Abnormal cytology can t hide anymore

Management of Abnormal Cervical Cytology and Histology

Cervical Cancer Prevention in the 21 st Century Changing Paradigms

Treatment of Cervical Intraepithelial Neoplasia. Case. How would you manage this woman?

LLETZ (Large Loop Excision of the Transformation Zone) Fragmentation: Impact on Margin Assessment and Cervical Biopsy-LLETZ Correlation

CONFRONTING CERVICAL CANCER

Department of Health Standard for the Cervical Cancer Screening Program. Approval Date: 08 May 2018 Effective Date: 13 May 2018

European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs

SCREENING FOR CERVICAL CANCER: REVISED

Hyperchromatic Crowded Groups: What is Your Diagnosis? Session 3000

idc 20 AUTOMATED LIQUID-BASED CYTOLOGY SLIDE PREPARATION SYSTEM

The new Cervical Screening Test for Australian women: Louise Farrell

What is a Pap smear?

Outcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure

Your Colposcopy Visit

BOSNIAN-TURKISH CYTOPATHOLOGY SCHOOL June 18-19, 2016 Sarajevo. Case Discussions. 60 year old woman Routine gynecologic control LBC

Cervicovaginal Flora Comparison of Conventional Pap Smears and a Liquid-Based Thin-Layer Preparation

HPV: cytology and molecular testing

SQUAMOUS CELLS: Atypical squamous cells (ASC) - of undetermined significance (ASC-US) - cannot exclude HSIL (ASC-H)

Prepared By Jocelyn Palao and Layla Faqih

Managament of Abnormal Cervical Cytology and Histology

Glandular lesions in cervical cytology. Margareta Strojan Fležar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia

Human Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?

Department of Pathology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen, Denmark

Suthi Sangkarat, Somsak Laiwejpithaya, Manee Rattanachaiyanont, Pattama Chaopotong*, Mongkol Benjapibal, Weerasak Wongtiraporn, Sujera Laiwejpithaya

The Renewed National Cervical Screening Program:

Transcription:

Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens 3 Christine Bergeron, MD, PhD Introduction Carcinoma of the cervix is a slow growing cancer, which is preceded by precancerous lesions named cervical intra-epithelial neoplasia (CIN). The slow progression of precancerous lesions allows detecting the lesion at this stage. The cervical smear allows detecting cytological abnormalities at the microscope. The cells are taken by a spatula or a brush, smeared on glasses and stained by the method of Papanicolaou. The screening by the conventional cervical smear has reduced the incidence and the mortality of cervical cancer (1). The interval between two smears is variable depending if the screening is organized or opportunistic. In the later case, a percentage of women do not have cervical smears, in particular women who are in precarious situation, immigrant women or postmenopausal women without treatment (2). Women who develop cervical cancer have not had a cervical screening or got it in a too spaced way in 60% of cases. In 10% of cases, they had a smear but not an appropriate follow-up. At least, in 30% of cases, they had a regular cervical smear. In this case, cancer is due to a false negative linked to the sampling or to the interpretation. Terminology of Cervical Smears Specimen Adequacy Sampling quality was one of the most innovative proposals made in the Bethesda terminology in 1988. Three categories were proposed: satisfactory, satisfactory but limited, and unsatisfactory. The second category was used for smears not containing endocervical or metaplastic cells, which are the proof of sampling the transformation zone, or partial inflammatory smears. This category was eliminated since clinicians felt obliged to redo the smears. It is now suggested that along with the evaluation of smears, note should be made regarding the presence of less than 10 endocervical cells, inflammation clouding evaluation of less than 75% of the smear, and that the clinician must make the decision whether or not to redo a new smear. If the inflammation, blood and cellular debris clouding are more than 75% of the smear, it should be considered unsatisfactory. Between 8000 and 12000 squamous cells must be present in a conventional smear, and 5000 cells for a liquid smear. Smears with paucicellularity, without appropriate patient identification, or those, which arrive broken, must also be considered unsatisfactory. Interpretation/Results Negative for Intraepithelial Lesion or Malignancy Table I summarizes the Bethesda 2001 System (3). The category absence of intraepithelial squamous lesion or suspected malignant cell regroups the categories normal and benign alterations (Figure 1). Microorganisms replace the term infection. Alterations due to inflammation, irradiation, or the presence of an intrauterine contraceptive device (IUD) are classified within normal smears. Epithelial Squamous Cell Abnormalities Atypical Squamous Cells (ASC) Following numerous discussions, based on the practicality of maintaining or not an invalid category, it has been decided to keep this category, which is associated with approximately 10% of high grade CIN or CIN2+ from biopsies. On the other hand, the subdivisions of this category have been modified (Table I). The general term for this category is no longer atypical cells of undetermined significance (ASCUS). It is Figure 1. Normal superficial and intermediate squamous cells in a clean background. 16

Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens u 17 Table 1. The 2001 Bethesda System. SPECIMEN ADEQUACY Satisfactory for evaluation Unsatisfactory for evaluation because of (specify reason) DESCRIPTIVE DIAGNOSES NON NEOPLASTIC Negative for intraepithelial lesion or malignancy (include in the absence of neoplastic abnormalities, with or without entities listed below) MICROORGANISMS: Trichomonas vaginalis Fungal organisms morphologically consistent with Candida Shift in vaginal flora suggestive of bacterial vaginosis Bacteria morphologically consistent with Actinomyces Cellular changes associated with Herpes simplex virus Reactive cellular changes associated with Inflammation (includes typical repair) Radiation Intrauterine contraceptive device (IUD) Benign-appearing glandular cells status-post hysterectomy Figure 2. Atypical squamous cells of undetermined significance (ASC- US): there is slight increase of the nucleus ( ) on few superficial cells. OTHER Endometrial cells (in a woman 40) EPITHELIAL CELL ABNORMALITIES SQUAMOUS CELL Atypical squamous cells Undetermined significance (ASC-US) Not exclude HSIL (ASC-H) Low grade squamous intraepithelial lesion (LSIL) encompassing: HPV/mild dysplasia/cin 1. High grade squamous intraepithelial lesion (HSIL) encompassing: moderate and severe dysplasia, CIS/CIN 2 and CIN 3 Squamous cell carcinoma GLANDULAR CELL Atypical Endocervical cells Endometrial cells Glandular cells Atypical glandular/endocervical cells, favor neoplastic Endocervical adenocarcinoma in situ Adenocarcinoma (endocervical, endometrial, extrauterine, NOS). Figure 3. Atypical squamous cells cannot exclude HSIL (ASC-H): there is increase of the nuclear-cytoplasm ratio ( ) on only one group of basal cells. replaced by the term atypical squamous cells. The term atypical squamous cells of undetermined significance (ASC-US) will be used for abnormalities suggesting a lowgrade intraepithelial squamous lesion, which has not been confirmed, or for non-specific atypical cells (Figure 2). Not more than 3% of the smears should have this designation. Atypical findings of undetermined significance associated with inflammation come out of this group and should now be included among normal smears. The term atypical squamous cells not permitting exclusion of a high grade intraepithelial squamous lesion (ASC-H) is proposed for those unconfirmed, although suspected of high-grade intraepithelial squamous lesion (HSIL) (Figure 3). This term should apply to 5-10% of atypical squamous cell alterations and are often associated with a high grade CIN confirmed through biopsy taken by colposcopy. Squamous Intraepithelial Lesion The Bethesda 2001 system has the same 2 categories as proposed in 1988, which are low grade intraepithelial squamous lesion (LSIL) (Figure 4) and high grade intraepithelial squamous lesion (HSIL) (Figure 5) (Table I). Precancerous and invasive cancer is associated with a highrisk human papillomavirus (HPV) infection in 95% of the cases. HPV is a highly infectious virus; most of infections are latent and regress spontaneously without intervention. Neoplasia is a very rare event and a complication of HPV infection. This infection may be productive. It is characterized by the presence of koilocytosis and corresponds to LSIL according to the Bethesda terminology. LSIL (1% of the smears) regress spontaneously in at least half of cases, especially in young patients. They evolve slowly to a HSIL only in 20% of cases.

18 u Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens Figure 4. Low grade squamous intraepithelial lesion (LSIL): there are koilocytes ( ) on superficial cells. Abnormalities of basal cells define HSIL. HSIL (0.5% of the smears) are associated with persistent viral infection and with high grade CIN detected from biopsy and can progress to an invasive lesion. Epithelial Glandular Cell Abnormalities Atypical Glandular Cells (AGC) The term atypical endocervical, endometrial or glandular cells replaces the term atypical glandular cells of undetermined significance (AGUS) (Table 1). The nature of glandular, endocervical or endometrial cells should be noted; this will permit a more appropriate diagnostic approach, cervical biopsy, and examination of the endocervix to identify endocervical lesion, or endometrial biopsy to identify an endometrial lesion. Figure 6. Adenocarcinoma in situ (AIS): Endocervical nuclei have a ). feathering and palissading appearance ( Endocervical Adenocarcinoma in situ (AIS) In situ adenocarcinoma is a new category, which corresponds to specific morphological abnormalities (Figure 6); some have already been using this term for several years. These abnormalities, which are based on morphological changes, permit to differentiate AIS from invasive adenocarcinomas of endocervical origin. This category allows for a more aggressive diagnostic approach such as a conization if the initial diagnostic findings are negative or for the complete ablation of the lesion. Adenocarcinoma The category atypical glandular or endocervical cells suggesting neoplasia is badly defined on morphological grounds. It should permit early identification of intraepithelial glandular lesions even though it requires prospective studies for confirmation. The category for invasive adenocarcinomas remains identical. Other Cervical cytology is not a good diagnostic assay for endometrial cancer. Morphologically benign endometrial cells were not mentioned in the 1988 Bethesda system, except referring to menopausal women. The category other is now proposed to classify smears without morphological abnormalities but which have apparently benign endometrial cells, in women over 40 years. The presence of these cells indicates an increased risk for endometrial cancer, and therefore an endometrial biopsy is recommended. Benign glandular cells found after hysterectomy should be noted as absence of malignant-like cells. The Conventional Smear Figure 5. High grade squamous intraepithelial lesion (HSIL): several ). basal cells have marked nuclear abnormalities ( The smear should be performed remotely of sexual activities (48 hours), outwards of menstrual periods, of local therapy or infection, and if necessary after estrogenic treatment for the

Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens u 19 menopausal woman. Vaginal touch should be avoided before taking a smear such as lubrificant. The sampling should concern the transformation zone, which is located most of the time around the external os, specifically in premenopausal women. The Ayre spatula is recommended with associated endocervical brush if the squamo-columnar junction is located in the endocervix. The Cervex Brush or a modified Ayre spatula allows sampling the cervical os and the endocervix simultaneously. The sampling is smeared on the glass in uniform pattern. The fixation should be done immediately. The Liquid Based Cytology The liquid based cytology (LBC) corresponds to a sampling where cells are put in suspension in a conversation liquid. For the clinician, the sample is made the same manner as that of the conventional smear by using a plastic brush, which can take the squamo-columnar junction and the endocervix, or by combining the use of a spatula and an endocervical brush. The taken material is then immediately rinsed in the bottle, which contains a fixative allowing transport to the laboratory. The clinician does not have to deal with any spreading, which is done at the laboratory. Currently, two technical methods, which use automats, were validated by Food and Drug Administration (FDA) and are used frequently. One is proceeding by filtration and collecting cells vacuum-packed on a membrane with transferring cells on a glass (ThinPrep, Cytyc ). The other is proceeding by centrifugation and sedimentation through a gradient of density (Surepath, Tripath Imaging ). Spreading out in thin layer which results from these techniques eliminates a great part of the inflammatory cells, necroses and of red blood cells, outcome to a cleaning of spreading out. The LBC makes it possible to avoid the majority of the artefacts of superposition of the conventional smear but the dispersion of the cellular material removes also usual visual reference marks. The cytologists are used to reading smears fixed in a liquid for the urines, the serosa or the ovaries. It imposes an analysis element by element and a training at least 6 months to readjust the morphological criteria. The cells are not flattened on the support but deposited and the pictorial aspects are some modified. The nuclei are not hyper chromatic any more but take a vesicular aspect. The cytoplasms are important to differentiate the cellular origin. The Quality of the Smear The performances were evaluated by several national agencies whose conclusions are convergent as for the improvement of the quality of the smear. The unsatisfactory smears or limited by the presence of inflammation and red blood cells are statistically less important with LBC than with the conventional method. The absence of cellular material due to a sampling of bad quality remains as frequent in LBC as in conventional smear. The presence of endocervical cells was evaluated of various manners. In the studies where the sampling was divided into a conventional spreading out and where the residual material was rinsed in the bottle (splitsamples), the endocervical cells are fewer in LBC. In the studies where all the sampling was rinsed in the flask and results compared retrospectively to those in which smearing was made in a conventional way, the absence of endocervical cells is the same in the two methods. Scotland was the first European country to integrate LBC in an organized screening program (4). This decision was made on the results of a study of 70 000 smears concerning 3 centers. Cost-efficiency calculation was for the benefit of LBC because the rate of inadequate smears passed from 7% with the conventional smear to 1% with the smear in liquid medium. The definition of an inadequate smear in Scotland and England includes the smears deprived of endocervical cells. This definition explains the high percentage of inadequate cells. In the pilot study made in England, the rate of definite inadequate smear according to criteria s of the National Health System Cervical Screening Programs (NHSCSP) is from 9.1% with the conventional smear to 1.6% with LBC (5). The Diagnostic Performance In the framework of the preparation of the new European Guidelines for Quality Assurance in Cervical Cancer Screening, a meta-analysis on test characteristics of LBC and conventional cytology (CP) was also prepared (6). Lowlevel and progressively higher-level inclusion criteria were considered on separated studies with concomitant testing and two-cohort studies. At the first level, studies that documented rates of cytological abnormality were accepted; at the second level, studies with colposcopic and histological verification of cytological positives were considered, and finally, at the third level, studies where all women were submitted to colposcopy and histology if colposcopic suspicion of lesions were selected. For all levels, ratios of test positivity (LBC/ CP) have been computed, in addition for the second and third level ratios of positive predictive values, and for the third level only, relative sensitivity and specificity. Results were compiled according to cytological cut-off ASC-US, LSIL and HSIL and histological outcome threshold CIN categories. Also, the ratios of the proportion of unsatisfactory preparations and the duration of interpretation were analyzed. A series of test and study quality characteristics was established for multivariate analysis. 126 reports were retrieved from 109 studies matching selection criteria. Nevertheless, only 9 studies could be included in the third level meta-analysis. Results pooled from studies with concomitant testing showed nearly equal detection rates of HSIL and positive predictive value for CIN2+ in CP and LBC. However, in two-cohort studies, detection rates of HSIL were substantially and statistically significantly higher in LBC. The sensitivity and specificity of LBC at ASC-US+ and LSIL+ for CIN2+ pooled from studies of the third level never was significantly different from CP. In two-cohort studies, 34% (ratio: 0.66, CI: 0.42-1.02) and 83% (ratio: 0.17, CI: 0.10-0.32) less unsatisfactory smears were found in ThinPrep and AutoCyte/SurePath smears, respectively. Overall, interpretation of LBC required 30% less time to interpret than CP. It was concluded that no

20 u Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens evidence is available to claim higher accuracy of LBC to predict histologically confirmed CIN2+, but recognized that LBC improves the quality and speed of interpretation, and offers the possibility of additional molecular testing. Therefore both CP and LBC for screening in Europe are recommended. Preferences should be determined depending on local economical considerations. The Automatisation The smear in LBC was proposed in order to improve quality of cellular spreading out tracking and then make reading under the microscope easier but it was made to allow a reading under microscope more efficient too by cameras connected to computer software. The automated reading was created to increase cytology sensitivity by detecting small abnormal cells of squamous or glandular type, which are difficult to diagnostic in conventional reading. This should increase the specificity too by selecting only reproducible abnormalities. The automation of reading is made to increase productivity by excluding normal slides, by selecting abnormal pictures the pathologist must review. The Cost Choices of each country must be done on cost-efficiency studies, which are not transposable from one country to another. The over cost of LBC is more or less important according to the consumable, the equipment in material and the wages related to a manual or automated technique. The reimbursement of LBC in Europe varies from one country to another, but the majority of the systems of health reimburse LBC at the same price as the conventional smear. In England, the recommendations of NICE did not recommend a liquid medium of conservation rather than another (5). Certain countries authorize that the over cost is reimbursed by the private insurance, as in Germany, in Spain, in Italy or Portugal. This over cost is no more authorized in Switzerland since April 2003. smears by using one or two observers or by correlating the results with a biopsy made under colposcopy (2). This remains of course a model, which is not applicable in routine because the women having a normal smear do not have, most of the time, histological follow-up. The misreading led to recommendations of quality assurance, which are single with cytology. The reading of 10% of the smears taken randomly is part of the recommendations of Clinical Laboratory Improvement Amendments (CLIA). The fast second reading of the whole of the smears and the targeted second reading of a risk population (patients with antecedents of abnormal smears, HIV positive, having a sexually transmitted disease) are considered more effective to detect false-negative cytological reading. The other methods generally recommended to detect the negative ones in a retrospective way are the rereading of previous negative smears when abnormalities appear on a smear or a biopsy under colposcopy. References 1. International Agency for Research on Cancer World Health Organization. Cervix cancer screening. IARC Handbooks of cancer prevention, Vol 10, IARC Lyon 2005. 2. European guidelines for quality assurance in cervical cancer screening. Editors M Arbyn, M Antilla, J Jordan, G Ronco, U Schenck, N Segnan, HG Wiener, A Herbert, J Daniel, L von Karsa, IARC Lyon 2008. 3. Solomon D, Davey D, Kurman R, Moriarty A, O Connor D, Prey et al. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 2002, 287:2114-2119. 4. Scottish Cervical Screening Programme: Steering group report on the feasibility of introducing liquid-based cytology, January 2002. http://www.show.scot.nhs.uk. 5. National Institute for Clinical Excellence (NICE). Guidance on the use of liquid-based cytology for cervical screening. October 2003. http://www.nice.org.uk. 6. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared to cervical cytology: a systematic review. Obstet Gynecol 2008, 111, 167-77. The Quality Assurance The average ideal to control the quality of the cytological results would be to read again totality or a great part of the